CF PharmTech (2652.HK) Stock Price

CF PharmTech Price

CLOSED
5.18
​
Market closed

Over the last 3 years CF PharmTech grew revenue by 6.8% annually, reaching 429.98 M CNY. Earnings per share have declined at 72.0% per year over the last 2 years. For CF PharmTech, the net margin of 0.6% is up versus -14.0% a few years ago.

CF PharmTech stock price

Access this data via the Eulerpool API

CF PharmTech business model & stock analysis

CF PharmTech, Inc engages in the research, development, production and sale of respiratory diseases pharmaceutical products. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2025-10-08. The Company’s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The firm's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The firm mainly conducts its business in the domestic market.

Frequently asked questions about CF PharmTech

Converted at the current exchange rate, the CF PharmTech share trades at 0.69 EUR (5.18 CNY).

The revenue cannot currently be calculated for CF PharmTech.

The profit cannot currently be calculated for CF PharmTech.

The P/E ratio cannot be calculated for CF PharmTech at the moment.

The P/S cannot be calculated for CF PharmTech currently.

The Eulerpool Quality Score for CF PharmTech is 1/10.

The ISIN of CF PharmTech is CNE1000074R9. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of CF PharmTech is 2652.HK. The ticker symbol is used to trade CF PharmTech shares on the stock exchange.

Fair ValueTerminal
5.23 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Oct 8, 2025
ISIN
CNE1000074R9
Cusip
Y1R8BU106
Market capitalization
2.13 B CNYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.45
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
0.16 %
Last updated Oct 10, 2026, 9:38 PM

CF PharmTech Peer Group